Kane Biotech Inc

Kane Biotech, Inc. is a biotechnology company, which engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. The company is headquartered in Winnipeg, Manitoba. The company went IPO on 2003-05-07. The firm is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The firm has a portfolio of biotechnologies, intellectual property (65 patents and patents pending as well as trade secrets and trademarks) and products developed by Kane's own biofilm research and acquired from research institutions. DispersinB, coactiv+, DermaKB, DermaKB Biofilm, and revyve are trademarks of Kane Biotech Inc. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. The firm's other biofilm disruption technology is DispersinB. DispersinB is a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG). DispersinB cleaves PNAG, inhibiting bacterial adhesion and disperses the biofilm.